RS57275B1 - Tretman gihta i hiperurikemije - Google Patents

Tretman gihta i hiperurikemije

Info

Publication number
RS57275B1
RS57275B1 RS20180571A RSP20180571A RS57275B1 RS 57275 B1 RS57275 B1 RS 57275B1 RS 20180571 A RS20180571 A RS 20180571A RS P20180571 A RSP20180571 A RS P20180571A RS 57275 B1 RS57275 B1 RS 57275B1
Authority
RS
Serbia
Prior art keywords
gout
less
allopurinol
compound
cyclopropylnaphthalen
Prior art date
Application number
RS20180571A
Other languages
English (en)
Serbian (sr)
Inventor
Jeffrey Miner
Barry D Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57275(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of RS57275B1 publication Critical patent/RS57275B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20180571A 2010-06-15 2011-06-14 Tretman gihta i hiperurikemije RS57275B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
EP11796324.9A EP2582683B1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
RS57275B1 true RS57275B1 (sr) 2018-08-31

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180571A RS57275B1 (sr) 2010-06-15 2011-06-14 Tretman gihta i hiperurikemije

Country Status (19)

Country Link
US (3) US9216179B2 (enExample)
EP (1) EP2582683B1 (enExample)
JP (1) JP5964821B2 (enExample)
CA (1) CA2802407C (enExample)
CY (1) CY1120473T1 (enExample)
DK (1) DK2582683T3 (enExample)
ES (1) ES2670700T3 (enExample)
HR (1) HRP20180780T1 (enExample)
HU (1) HUE038265T2 (enExample)
LT (1) LT2582683T (enExample)
NO (1) NO2019008I1 (enExample)
PL (1) PL2582683T3 (enExample)
PT (1) PT2582683T (enExample)
RS (1) RS57275B1 (enExample)
SI (1) SI2582683T1 (enExample)
SM (1) SMT201800266T1 (enExample)
TR (1) TR201806828T4 (enExample)
WO (1) WO2011159732A1 (enExample)
ZA (1) ZA201300055B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
JP6976946B2 (ja) * 2015-12-08 2021-12-08 アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063788A1 (ja) 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
EA015846B1 (ru) 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
US20090042887A1 (en) 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
MX2011002450A (es) 2008-09-04 2011-05-25 Ardea Biosciences Inc Compuestos, composiciones y métodos para utilizar los mismos para modular niveles de ácido úrico.
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MY161482A (en) 2010-01-08 2017-04-14 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
US20130296345A1 (en) * 2010-10-15 2013-11-07 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
AU2011352129B2 (en) * 2010-12-30 2015-01-22 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
MX348281B (es) 2011-05-24 2017-06-02 Ardea Biosciences Inc * Hipertension e hiperuricemia.

Also Published As

Publication number Publication date
CY1120473T1 (el) 2019-07-10
WO2011159732A1 (en) 2011-12-22
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
TR201806828T4 (tr) 2018-06-21
JP5964821B2 (ja) 2016-08-03
JP2013528650A (ja) 2013-07-11
HRP20180780T1 (hr) 2018-07-13
ES2670700T3 (es) 2018-05-31
EP2582683A1 (en) 2013-04-24
PT2582683T (pt) 2018-05-25
SI2582683T1 (en) 2018-07-31
EP2582683A4 (en) 2014-04-30
US20190015392A1 (en) 2019-01-17
US9216179B2 (en) 2015-12-22
HUE038265T2 (hu) 2018-10-29
EP2582683B1 (en) 2018-03-21
US20160143889A1 (en) 2016-05-26
PL2582683T3 (pl) 2018-08-31
SMT201800266T1 (it) 2018-07-17
CA2802407A1 (en) 2011-12-22
CA2802407C (en) 2018-01-23
ZA201300055B (en) 2018-05-30
DK2582683T3 (en) 2018-06-06
NO2019008I1 (no) 2019-02-19

Similar Documents

Publication Publication Date Title
CA2802407C (en) Treatment of gout and hyperuricemia
CA2794798C (en) Treatment of gout
AU2013299841B8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
JP2024001009A (ja) Ｐｉ３ｋ阻害剤であるｇｄｃ－００７７による癌の治療方法
US12083129B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
US20110046119A1 (en) Therapeutic treatment
US20160129003A1 (en) Pharmaceutical Combinations
KR20240112931A (ko) 암 치료를 위한 cdk4 억제제
US20170224670A1 (en) Drug Combination to Treat Melanoma
EP4247363A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112898295A (zh) 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
US11389440B2 (en) PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
WO2015022657A1 (en) Pharmaceutical combinations
AU2008201290B2 (en) Therapeutic treatment
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
TW201315471A (zh) 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法